How to Value a Two-Phase Orthodontic Practice in 2026

Two-phase orthodontic practices are the trickiest valuation exercise in dental M&A. A typical general dental practice sells on trailing collections and SDE with relatively clean economics. An orthodontic practice that has a meaningful Phase 1 interceptive treatment program sits on a balance sheet full of deferred revenue obligations that legally transfer to the buyer at closing. Get the treatment plan accounting wrong, and the deal either blows up in due diligence or leaves $500K-$1M on the table.

I've closed enough two-phase ortho deals to know where the land mines are. Here's what every orthodontist needs to understand about valuation before going to market.

The Orthodontic Valuation Baseline

Orthodontic practices generally trade at 2.5-4.5x SDE to private buyers or 70-95% of annual collections. For platform-scale practices going to ortho-focused DSOs, expect 7-11x EBITDA for add-ons and 10-14x EBITDA for platform deals.

Orthodontic multiples have held up well compared to general dentistry because the specialty has favorable demographics (parents paying for kids' care), high insurance reimbursement, and a concentrated buyer pool. Smile Doctors (backed by Linden Capital and Thomas H. Lee Partners), OrthoSynetics, Specialty Dental Brands, and Align Technology's strategic partners have all been active consolidators.

But that headline multiple is misleading for two-phase practices, because the calculation of "collections" and "SDE" is where the complexity lives.

The Deferred Revenue Problem

Here's the core issue. When a parent signs a Phase 1 ortho contract for an 8-year-old — a typical 12-18 month interceptive treatment running $3,500-$5,500 — they usually pay a down payment of $500-$1,500, then monthly payments over the active treatment period. The practice collects cash, but the dentist is obligated to provide future services (monthly adjustments, appliances, retention, and often the transition into Phase 2 at age 11-13).

In most orthodontic practice management software (Dolphin, Cloud 9, Ortho2), the down payment and early installments show up as "collections" in your monthly reports. Your trailing 12-month collections number looks great. But a sophisticated buyer's diligence team will immediately ask: "How much of this collected cash represents services you still owe?"

The answer is your deferred revenue liability. For a practice doing 60-70% of its business in full-treatment ortho (Phase 1, Phase 2, or comprehensive adult), the deferred revenue balance typically runs 30-50% of trailing 12-month collections. On a $2M practice, that's $600K-$1M of cash the buyer inherits as a services-owed obligation.

Buyers handle this one of two ways. Either they require a working capital adjustment at closing that effectively transfers the deferred revenue balance back to the seller (reducing the purchase price dollar-for-dollar), or they bake it into a lower headline multiple. Either way, you pay for it.

Treatment Plan Documentation: The Make-or-Break Factor

If you do nothing else before going to market, document every active treatment plan in writing with the following information per patient: contract date, total contract value, down payment received, monthly payment amount, payments collected to date, payments remaining, current treatment phase (Phase 1 active, Phase 1 retention, Phase 2 pending, Phase 2 active, or comprehensive), expected treatment completion date, and whether the contract includes a Phase 2 commitment.

Why does this matter? Because buyers will not — and should not — close a two-phase orthodontic practice without this documentation. Every contract that obligates the buyer to provide future services without corresponding collected revenue is a liability that reduces the purchase price. Missing contracts get treated as full-value liabilities, which is the worst possible outcome for the seller.

I've seen two-phase practices lose $400K-$800K in purchase price because the seller couldn't produce a clean treatment plan schedule during diligence. Buyers assume the worst. Clean documentation changes the negotiation dynamic entirely — the buyer can price the liability accurately and stop assuming hidden downside.

Phase 1 to Phase 2 Contract Carry-Over

Two-phase orthodontics creates a unique legal question: when a parent signed a combined Phase 1/Phase 2 contract with you in 2023, does the new owner in 2026 have to complete Phase 2 at the original contracted price? In most cases, yes. That contract is an asset of the practice and transfers with the business.

This is where practices gain or lose real money in the deal. Buyers want to know: how many patients in your current active database have already paid for Phase 1 and are contractually entitled to Phase 2 at locked-in 2022 or 2023 prices? Every one of those patients represents committed future work with no incremental revenue, but the ongoing overhead cost of providing braces, wires, adjustments, and retention.

If you have 150 patients in the "waiting for Phase 2" bucket who paid $5,000 for combined treatment in 2022, and 2026 comprehensive treatment runs $6,800, you're effectively transferring $270K of inflation loss to the buyer. They will subtract it.

The sellers who navigate this best have clean contracts that specify Phase 2 pricing as "to be determined at start of Phase 2 treatment at then-current office fees" rather than a locked combined fee. If your current contracts lock combined pricing, there's not much you can do for existing patients — but you should absolutely update your contract template for new patients before going to market.

Starts Per Month: The Forward-Looking Metric Buyers Watch

Historical collections tell a buyer what your practice did. New starts per month tell them what it's going to do. For orthodontics, new starts are the single best leading indicator of next-year revenue.

Healthy benchmarks for a solo orthodontic practice: 25-40 new starts per month (combining Phase 1, Phase 2, and comprehensive adult). Practices doing 15 starts or fewer are flagged as declining. Practices doing 50+ are flagged as exceptional and trade at the top of the multiple range.

Buyers will ask for 36 months of new-starts data, segmented by treatment type. If your Phase 1 starts have been declining, that's a yellow flag because it signals your referral relationships with general dentists are weakening. If your adult comprehensive starts have been declining, that's often a red flag because adult work is the highest-margin segment and the demographic that's most sensitive to marketing and reputation.

Practices that can show 24 months of flat or growing new starts in all three segments trade at the top of the ortho range. Practices with declining starts typically see 15-25% haircuts from the baseline multiple.

Referral Source Concentration

Orthodontic practices live or die on referrals from general dentists and pediatric dentists. This creates a concentration risk that buyers underwrite carefully.

Pull a referral source report for the last 24 months. If your top three referring practices generate 35%+ of your new starts, you have a concentration problem. Buyers will discount accordingly because they know referral relationships are personal, often built over decades, and don't transfer automatically to a new owner. Losing a top referrer after closing can wipe out 10-15% of new starts overnight.

The best-valued ortho practices have diversified referral bases: no single referring practice represents more than 10% of starts, and the top ten referrers collectively represent 40-50% of starts. The rest comes from patient word-of-mouth, Google, Instagram, and orthodontist-controlled marketing.

The Math on a Typical Two-Phase Practice

Consider a single-location orthodontic practice in a suburban market: $2.4M trailing 12-month collections, 30 new starts per month, 55% Phase 1/Phase 2 combined contracts, $780K SDE (32.5% margin), one owner-orthodontist plus two assistants and a treatment coordinator.

Headline valuation on SDE alone: 3.5x SDE = $2.73M. But then the deferred revenue adjustment kicks in. The practice carries roughly $950K of deferred revenue (services-owed obligations) on the balance sheet. After a working capital adjustment of roughly $750K (the portion of deferred revenue that represents cash collected but services not yet provided), the seller actually nets closer to $1.98M.

To a DSO like Smile Doctors, the same practice converts to roughly $520K EBITDA after replacing owner comp. At 9x, headline is $4.68M — but again, the deferred revenue adjustment reduces net proceeds meaningfully. With DSOs, these adjustments are sometimes structured as reductions to the equity rollover rather than cash at close, which affects the tax treatment but not the overall economics.

The lesson: the headline multiple on an ortho practice rarely equals the actual check you take home. Understanding the deferred revenue haircut before going to market is how you avoid being surprised at closing.

Preparing a Two-Phase Practice for Sale

The prep priorities are different from general dentistry. Focus on: (1) clean treatment plan documentation with deferred revenue quantified monthly; (2) 36 months of new-starts data segmented by treatment type; (3) referral source diversification; (4) updated contract templates that don't lock Phase 2 pricing; and (5) associate coverage that can complete in-process Phase 2 treatments after your transition.

For broader context on how orthodontics fits in the dental specialty M&A landscape, see our dental practice valuation guide. And for the broader exit timeline, the preparing your business for sale playbook applies, though orthodontic-specific items like treatment plan scheduling and deferred revenue quantification need to be started earlier than in general dentistry — ideally 24 months before going to market.

The Bottom Line

Two-phase orthodontic practices have the highest gap between headline valuation and net seller proceeds in all of dental M&A. The deferred revenue liability is real, the contract carry-over to buyers is real, and the treatment plan documentation is non-negotiable. Orthodontists who understand these dynamics 24 months before selling — and fix their contract templates, clean up their treatment plan reporting, and diversify their referral base — consistently get 15-25% higher net proceeds than orthodontists who just show up with a trailing 12-month collections report and expect 3.5x SDE. The diligence in this specialty is unforgiving, but it rewards preparation generously.